Cholelithiasis: epidemiological data, key aspects of the pathogenesis and comorbidity, relevant therapeutic targets

Abstract

The article is devoted to current scientific data on the cholelithiasis pathogenesis and opportunities for optimizing litholytic therapy. It is shown that cholelithiasis should be considered as a topical manifestation of systemic disorders of metabolic and inflammatory genesis throughout the body. The article shows the key role in the development of its insulin resistance, imbalanced cholesterol and bile acid metabolism, biliary dyskinesia, and the production of inflammatory mediators. There are factors that cause cholelithiasis comorbidity with cardiovascular diseases, cerebrovascular diseases, gastrointestinal cancer of various localization, and liver diseases. The role of cholelithiasis as a risk factor and a criterion for an adverse prognosis is justified. Pathogenetically justified method for improving oral litholysis, which provides a complex therapy effect, is considered; the rationality of using a fixed combination of ursodeoxycholic acid and glycyrrhizic acid is justified. KEYWORDS: gallstone disease, cholelithiasis, cholesterol stones, oral litholysis, ursodeoxycholic acid, glycyrrhizic acid, complex therapy, metabolic disorders. FOR CITATION: Nikitin I.G., Volnukhin A.V. Cholelithiasis: epidemiological data, key aspects of the pathogenesis and comorbidity, relevant therapeutic targets. Russian Medical Inquiry. 2020;4(5):290–296. DOI: 10.32364/2587–6821–2020–4-5-290-296.